Literature DB >> 15198511

Assessment of fertility in male rats after extended chemical castration with a GnRH antagonist.

Susan S D'Souza1, Francesca Selmin, Santos B Murty, Wei Qiu, B C Thanoo, Patrick P DeLuca.   

Abstract

The purpose of this study was to assess whether male rats whose testosterone levels were suppressed to castration levels (<0.5 ng/mL) for a 1-year period by the sustained delivery of orntide acetate, a GnRH antagonist, would return to fertility (ie, produce offspring) after serum testosterone returned to control levels. Male rats comprising a treatment group (orntide microspheres, dose = 27 mg/kg/y), a vehicle control group, and a control group of proven male breeders were used. For the treatment and vehicle control groups, serum orntide and testosterone levels were monitored at periodic intervals for 14 months from the initiation of treatment. After serum testosterone levels returned to vehicle control levels and orntide serum levels were no longer discernible for the treated group, each of the animals was housed with 2 drug-naive, female, proven breeders. All the breeder females produced offspring with the exception of 1 female housed with a male rat from the treatment group and the 2 females housed with a single male rat from the vehicle control group. The mean size and weight of the litters from each group were not statistically different. Further, fertility of the offspring from each group was assessed. The male and female offspring studied were all shown to be fertile. The results suggest that lack of fertility due to testosterone suppression in male rats is reversible after cessation of treatment with the GnRH analog, orntide.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198511      PMCID: PMC2750945          DOI: 10.1208/ps060110

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  18 in total

1.  One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-10-13       Impact factor: 15.470

2.  Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-10-13       Impact factor: 15.470

3.  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.

Authors:  D McLeod; N Zinner; K Tomera; D Gleason; N Fotheringham; M Campion; M B Garnick
Journal:  Urology       Date:  2001-11       Impact factor: 2.649

4.  Meta-analysis and economic evaluation of LH-RH agonists' depot formulations in advanced prostatic carcinoma.

Authors:  Karine Alloul; Luc Sauriol; Louise Lafortune
Journal:  Can J Urol       Date:  1998-08       Impact factor: 1.344

5.  Preparation, characterization, and in vitro evaluation of 1- and 4-month controlled release orntide PLA and PLGA microspheres.

Authors:  J W Kostanski; B C Thanoo; P P DeLuca
Journal:  Pharm Dev Technol       Date:  2000       Impact factor: 3.133

6.  Assessment of a two-generation reproductive and fertility study of mercuric chloride in rats.

Authors:  A Atkinson; S J Thompson; A T Khan; T C Graham; S Ali; C Shannon; O Clarke; L Upchurch
Journal:  Food Chem Toxicol       Date:  2001-01       Impact factor: 6.023

Review 7.  Development of GnRH antagonists for prostate cancer: new approaches to treatment.

Authors:  T Cook; W P Sheridan
Journal:  Oncologist       Date:  2000

Review 8.  Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

Authors:  I M Thompson; E J Zeidman; F R Rodriguez
Journal:  J Urol       Date:  1990-12       Impact factor: 7.450

9.  Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.

Authors:  Ida Pucarelli; Maria Segni; Massimiliano Ortore; Elena Arcadi; Anna Maria Pasquino
Journal:  J Pediatr Endocrinol Metab       Date:  2003-09       Impact factor: 1.634

10.  3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial.

Authors:  D Fontana; M Mari; A Martinelli; C Boccafoschi; C Magno; M Turriziani; S S Maymone; S Cosciani Cunico; A Zanollo; G Montagna; M Frongia; U Jacobellis
Journal:  Urol Int       Date:  2003       Impact factor: 2.089

View more
  7 in total

1.  A short term quality control tool for biodegradable microspheres.

Authors:  Susan D'Souza; Jabar A Faraj; Rossella Dorati; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2014-02-12       Impact factor: 3.246

2.  Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.

Authors:  Chris P Miller; Maysoun Shomali; C Richard Lyttle; Louis St L O'Dea; Hillary Herendeen; Kyla Gallacher; Dottie Paquin; Dennis R Compton; Bishwabhusan Sahoo; Sean A Kerrigan; Matthew S Burge; Michael Nickels; Jennifer L Green; John A Katzenellenbogen; Alexei Tchesnokov; Gary Hattersley
Journal:  ACS Med Chem Lett       Date:  2010-12-02       Impact factor: 4.345

3.  A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres.

Authors:  Susan S D'Souza; Jabar A Faraj; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2005-10-31       Impact factor: 3.246

Review 4.  Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects.

Authors:  Heidi M Mansour; Minji Sohn; Abeer Al-Ghananeem; Patrick P Deluca
Journal:  Int J Mol Sci       Date:  2010-09-15       Impact factor: 5.923

5.  Development of Risperidone PLGA Microspheres.

Authors:  Susan D'Souza; Jabar A Faraj; Stefano Giovagnoli; Patrick P Deluca
Journal:  J Drug Deliv       Date:  2014-01-28

6.  Preparation, Characterization, and In Vivo Evaluation of Olanzapine Poly(D,L-lactide-co-glycolide) Microspheres.

Authors:  Susan D'Souza; Jabar A Faraj; Stefano Giovagnoli; Patrick P DeLuca
Journal:  J Pharm (Cairo)       Date:  2013-08-12

7.  IVIVC from Long Acting Olanzapine Microspheres.

Authors:  Susan D'Souza; Jabar A Faraj; Stefano Giovagnoli; Patrick P Deluca
Journal:  Int J Biomater       Date:  2014-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.